Circulating Trends of Influenza and Other Seasonal Respiratory Viruses among the US Department of Defense Personnel in the United States: Impact of the COVID-19 Pandemic

Wenping Hu 1,2,*, Anthony C. Fries 3, Laurie S. DeMarcus 1,2, Jeffery W. Thervil 1,2, Bismark Kwaah 1,2, Kayla N. Brown 1,2, Paul A. Sjoberg 1,2 and Anthony S. Robbins 1

1 The Department of Defense Global Emerging Infections Surveillance Branch, Armed Forces Health Surveillance Division, Wright-Patterson Air Force Base, Dayton, OH 45433, USA; laurie.demarcus.ctr@us.af.mil (L.S.D.); jeffrey.thervil.ctr@us.af.mil (J.W.T.); bismark.kwaah.ctr@us.af.mil (B.K.); kayla.brown.16.ctr@us.af.mil (K.N.B.); paul.sjoberg.1.ctr@us.af.mil (P.A.S.); anthony.robbins.5@us.af.mil (A.S.R.)
2 JYG Innovations LLC, Dayton, OH 45414, USA
3 U.S. Air Force School of Aerospace Medicine, Wright-Patterson Air Force Base, Dayton, OH 45433, USA; anthony.fries.1@us.af.mil

* Correspondence: wenping.hu.ctr@us.af.mil

Abstract: The objective of this study was to evaluate the impact of the COVID-19 pandemic on the circulation of influenza and other seasonal respiratory viruses in the United States. All data were obtained from the US Department of Defense Global Respiratory Pathogen Surveillance Program over five consecutive respiratory seasons from 2016–2017 through to 2020–2021. A total of 62,476 specimens were tested for seasonal respiratory viruses. The circulating patterns of seasonal respiratory viruses have been greatly altered during the pandemic. The 2019–2020 influenza season terminated earlier compared to the pre-pandemic seasons, and the 2020–2021 influenza season did not occur. Moreover, weekly test positivity rates dramatically decreased for most of the seasonal respiratory viruses from the start of the pandemic through spring 2021. After the easing of non-pharmaceutical interventions (NPIs), circulations of seasonal coronavirus, parainfluenza, and respiratory syncytial virus have returned since spring 2021. High rhinovirus/enterovirus activity was evident throughout the 2020–2021 respiratory season. The findings suggest a strong association between the remarkably changed activity of seasonal respiratory viruses and the implementation of NPIs during the COVID-19 pandemic. The NPIs may serve as an effective public health tool to reduce transmissions of seasonal respiratory viruses.

Keywords: influenza; respiratory virus; SARS-CoV-2; surveillance; pandemic

1. Introduction

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) spreads globally, resulting in an unprecedented public health crisis [1]. As of the end of the 2020–2021 respiratory season, it has been over one and a half years since the World Health Organization declared the COVID-19 pandemic in March 2020. During this time, policy makers worldwide have implemented stringent non-pharmaceutical interventions (NPIs) strategies such as lockdown, travel restrictions, and personal/social protective measures, in order to reduce the transmission of SARS-CoV-2 [2,3]. Meanwhile, the implementation of such public health measures appears to have exerted great impacts on the incidence of seasonal respiratory viruses. Studies conducted in both Northern [4–7] and Southern hemispheres [8–11] demonstrated that the percentage of infection with seasonal respiratory viruses dramatically decreased during much of 2020 and early 2021. Moreover, delayed activity of the respiratory syncytial virus (RSV) was observed [12,13]. With increasing uptake of vaccination against SARS-CoV-2, NPIs have been relaxed to varying extents in
different parts of the United States since March 2021. It is unknown whether the seasonal respiratory viruses would continue to be markedly decreased in the late phase of the 2020–2021 season, and further into the next respiratory season. Year-round respiratory virus surveillance is of clinical importance [14]. Therefore, it is crucial to continue to closely monitor the circulation of influenza and other seasonal respiratory viruses, and determine how the ongoing pandemic may affect the transmission patterns of those viruses.

Every year, the Department of Defense Global Respiratory Pathogen Surveillance (DoDGRS) program performs routine respiratory pathogen surveillance among the Department of Defense’s service members and their beneficiaries. The objective of this study was based on the DoDGRS data collected over five consecutive influenza seasons (2016–2021), to characterize circulating trends of influenza and other seasonal respiratory viruses among the Department of Defense personnel in the United States during the COVID-19 pandemic, and to compare the trends with those that occurred in the pre-pandemic period.

2. Methods
2.1. Surveillance Data

We obtained respiratory pathogen surveillance data on US Department of Defense personnel from the DoDGRS program over five consecutive respiratory seasons from 2016–2017 to 2020–2021. All patients seeking outpatient medical care were selected at sentinel or participating sites throughout the United States, using criteria which meet an influenza-like illness (ILI) case definition. ILI is defined as a patient presenting with (1) a fever (≥38 °C) and a cough or sore throat within 72 h after illness onset, or (2) symptoms determined by a physician to be an ILI case. Respiratory specimens were collected from ILI patients by nasopharyngeal wash or nasopharyngeal swab, and tested via a multiplex respiratory pathogen panel. In addition, a reverse transcription polymerase chain reaction (RT-PCR) and/or viral culture were used to identify and confirm the influenza viruses and other seasonal respiratory pathogens. If the respiratory specimen tested positive for influenza virus, further testing was conducted to identify the influenza virus type and subtype/lineage. During the COVID-19 pandemic, patients who tested for both seasonal respiratory viruses and SARS-CoV-2 were not included for analysis, due to possible changes in test eligibility and testing procedure in detecting respiratory viruses.

2.2. Statistical Analysis

The weekly test positivity rate for each respiratory virus in a given respiratory season was defined as the percentage of the number of cases over the total number of tests for the epidemic week under surveillance. By using the same thresholds in the study of Feng et al. [15], the start of an influenza epidemic period was defined as the first week during which the weekly test positivity rate was >10% and remained >10% for at least two consecutive weeks. The end of an influenza epidemic period was defined as the last week during which the positivity rate was >10% and remained >10% for at least two consecutive weeks before decreasing to <10%. The duration of the influenza epidemic period was then calculated.

The four-week averages of test positivity rates of non-influenza seasonal respiratory viruses during the COVID-19 pandemic were compared with those in the pre-pandemic (average for three previous seasons, 2016–2017 through 2018–2019), using the GLM procedures of SAS (SAS Enterprise Guide 7.1, SAS Institute Inc., Cary, NC, USA) with the model

\[ Y_i = \mu + T_i + e_i, \]

where \( \mu \) = overall mean; \( T_i \) = effect of treatment (treatment was the COVID-19 pandemic and the pre-pandemic, \( i = 1, 2 \)); and \( e_i \) = error term. A \( p < 0.05 \) was considered statistically significant.

3. Results

Influenza and other seasonal respiratory viruses detected over five respiratory seasons (2016–2017 through 2020–2021) are shown in Table 1. During the five respiratory seasons, a
total of 62,476 tests for detection of seasonal respiratory viruses were performed; among which 13,536 (21.7%) were positive for influenza, 634 (1.0%) for adenovirus, 2189 (3.5%) for seasonal coronavirus, 1338 (2.1%) for human metapneumovirus, 1208 (1.9%) for parainfluenza, 1649 (2.6%) for RSV, and 6687 (10.7%) for rhinovirus/enterovirus. Of the total 13,536 influenza viruses detected, influenza A(H1N1)pdm09, influenza A(H3N2), and influenza B were 3769 (27.8%), 4624 (34.2%), and 3621 (26.8%), respectively, with the remaining being 1475 (10.9%) non-subtyped influenza A and 47 (0.3%) dual influenza viruses (Table 1).

| Pathogen                             | Number of Specimens in Respiratory Virus Season | Overall | 2016–2017 | 2017–2018 | 2018–2019 | 2019–2020 | 2020–2021 |
|--------------------------------------|-----------------------------------------------|---------|-----------|-----------|-----------|-----------|-----------|
| Influenza A(H1N1)pdm09               |                                               |         |           |           |           |           |           |
| Single infection                     |                                               | 3430    | 28        | 393       | 835       | 2173      | 1         |
| Co-infection                         |                                               | 339     | ND        | 41        | 57        | 241       | ND        |
| Influenza A(H3N2)                    |                                               | 4286    | 1252      | 1426      | 1483      | 72        | 53        |
| Single infection                     |                                               | 338     | 2         | 161       | 153       | 15        | 7         |
| Co-infection                         |                                               | 1465    | ND        | 6         | 1426      | 33        | ND        |
| Influenza A/Not subtyped             |                                               | 10      | ND        | 1         | 3         | 6         | ND        |
| Influenza B                          |                                               | 2378    | 424       | 713       | 125       | 1113      | 3         |
| Single infection                     |                                               | 1243    | 1         | 258       | 40        | 944       | ND        |
| Co-infection                         |                                               | 47      | 4         | 17        | 3         | 23        | ND        |
| Dual influenza                       |                                               | 491     | 42        | 92        | 110       | 229       | 18        |
| Non-influenza virus                  |                                               | 33,121  | 2310      | 2945      | 11,440    | 12,511    | 3915      |
| Adenovirus                           |                                               | 634     | 75        | 107       | 235       | 197       | 20        |
| Seasonal coronavirus                 |                                               | 2189    | 110       | 503       | 633       | 763       | 180       |
| Human metapneumovirus                |                                               | 1338    | 91        | 320       | 203       | 681       | 43        |
| Parainfluenza                        |                                               | 1208    | 195       | 187       | 321       | 327       | 178       |
| Respiratory syncytial virus          |                                               | 1649    | 175       | 398       | 378       | 573       | 125       |
| Rhinovirus/Enterovirus               |                                               | 6687    | 344       | 992       | 1214      | 2692      | 1445      |
| Co-infection                         |                                               | 1623    | 131       | 366       | 392       | 599       | 135       |
| Other pathogen                       |                                               | 491     | 42        | 92        | 110       | 229       | 18        |
| No pathogen detected                 |                                               | 33,121  | 2310      | 2945      | 11,440    | 12,511    | 3915      |

| Table 1. Influenza and other seasonal respiratory viruses detected over five respiratory seasons from 2016–2017 to 2020–2021. |

a Co-infection: co-infection with one or more non-influenza pathogens. b ND: not detected.

During three pre-pandemic influenza seasons (2016–2017 through 2018–2019), the influenza epidemic period started in as early as week 46 (18–24 November 2017) and ended in as late as week 19 (13–19 May 2017), lasting an average period of 21.7 weeks (range: 17–24 weeks) (Table 2). During the 2019–2020 respiratory season, influenza activity decreased rapidly after the United States declaration of the state of emergency in response to the COVID-19 pandemic on 13 March 2020 (Figure 1A,C and Figure 2). The influenza epidemic period of the 2019–2020 season ended in week 11 (14–20 March 2020), which was earlier compared to three previous influenza seasons (Table 2). Thereafter, the weekly positivity rates of influenza decreased from 8.4% in week 12 to 2.7% in week 13. The detection of influenza further decreased to near absence through the end of the 2019–2020 season. Moreover, the 2020–2021 influenza season did not occur. During the entire 2020–2021 respiratory season, there were a total of four influenza-positive cases including one influenza A(H1N1)pdm09 and three influenza B detected from 5518 specimens from the beginning through week 36. This was followed by increased influenza A (H3N2) circulation in the last
three weeks 37–39 [5 (2.7%) in week 37; 20 (10.6%) in week 38; and 35 (15.4%) in week 39] (Figure 2).

Figure 1. Cont.
Figure 1. (A–I) Weekly test positivity rate of seasonal respiratory viruses over five respiratory seasons from 2016–2017 to 2020–2021. Epidemic week is the week of the epidemiologic year for which there is the National Notifiable Diseases Surveillance System (NNDSS) disease report, the United States.

Table 2. Characteristics of seasonal pattern of influenza activity over five respiratory seasons from 2016–2017 to 2020–2021.

| Variable a | 2016–2017 | 2017–2018 | 2018–2019 | 2019–2020 | 2020–2021 |
|------------|-----------|-----------|-----------|-----------|-----------|
| Start of epidemic period | | | | | |
| Epidemic week | 48 | 46 | 52 | 46 | / |
| Date | 3–9 December 2016 | 18–24 November 2017 | 29 December 2018–4 January 2019 | 16–22 November 2019 | / |
| End of epidemic period | | | | | |
| Epidemic week | 19 | 17 | 16 | 11 | / |
| Date | 13–19 May 2017 | 28 April–4 May 2018 | 20–26 April 2019 | 14–20 March 2020 | / |
| Duration of epidemic period, week | 24 | 24 | 17 | 18 | / |
| Peak rate of test positivity | | | | | |
| Level, % | 49.6 | 53.7 | 43.7 | 47.5 | / |
| Epidemic week | 8 | 52 | 7 | 7 | / |
| Date | 25 February–3 March 2017 | 30 December 2017–7 January 2018 | 16–22 February 2019 | 15–21 February 2020 | / |

a Epidemic week is the week of the epidemiologic year for which there is the National Notifiable Diseases Surveillance System (NNDSS) disease report, the United States. b The 2020–2021 influenza season did not occur.
The four-week average positivity rates for non-influenza seasonal respiratory viruses are shown in Figure 3A,G. During the 2019–2020 season, starting in week 12–15 (12 March–17 April 2020), the four-week average positivity rates for all non-influenza seasonal respiratory viruses (excluding rhinovirus/enterovirus) dramatically decreased or were sustained at very low levels compared to those in the pre-pandemic. As for rhinovirus/enterovirus, the four-week average positivity rates decreased from 8.5% in week 12–15 (21 March–17 April 2020) to 4.7% in week 20–23 (16 May–12 June 2020), then started to increase to 12.9% by week 24–27 (13 June–10 July 2020), and remained at the pre-pandemic levels through the end of the 2019–2020 season. During the 2020–2021 season, there were persistently low circulations of adenovirus and human metapneumovirus, excepting for an uptick (6.4%; \( p < 0.05 \)) observed for human metapneumovirus at the beginning of the 2020–2021 season (Figure 3A,C). In contrast, the activities of seasonal coronavirus, parainfluenza, and RSV continued to be at very low levels following the end of the 2019–2020 season, but started to increase in the 2020–2021 season around week 8–11 (27 February–26 March 2021), then reached pre-pandemic levels or even higher (Figure 3B,D,E). Throughout the entire 2020–2021 season, the four-week averages of positivity rates of rhinovirus/enterovirus were mostly higher \( (p < 0.05) \) than those in the pre-pandemic, correspondingly (Figure 3F). During the 2020–2021 season, the activity of overall non-influenza seasonal respiratory viruses started to rise in week 8–11 (27 February–26 March 2021), then increased to 41.7% by week 16–19 (24 April–21 May 2021), and remained at high levels through the end of the 2020–2021 season, peaking at a four-week average positivity rate of 57.9% in week 24–27 (19 June–16 July 2021) (Figure 3G).

Figure 2. Seasonal activity of overall influenza including influenza A(H1N1)pdm09, influenza A(H3N2), and influenza B in respiratory seasons from 2016–2017 to 2020–2021. Epidemic week is the week of the epidemiologic year for which there is the National Notifiable Diseases Surveillance System (NNDSS) disease report, the United States. There are 53 weeks exceptionally in the 2020–2021 season, the positivity rate of overall influenza in week 53 was zero, and not shown in graph.
Figure 2. Seasonal activity of overall influenza including influenza A(H1N1)pdm09, influenza A(H3N2), and influenza B in respiratory seasons from 2016–2017 to 2020–2021. Epidemic week is the week of the epidemiologic year for which there is the National Notifiable Diseases Surveillance System (NNDSS) disease report, the United States. There are 53 weeks exceptionally in the 2020–2021 season, the positivity rate of overall influenza in week 53 was zero, and not shown in graph.

Figure 3. (A–G) Four-week average positivity rate of non-influenza seasonal respiratory viruses. Epidemic week is the week of the epidemiologic year for which there is the National Notifiable Diseases Surveillance System (NNDSS) disease report, the United States. For the 2019–2020 season, data started from week 12–15. There are 53 weeks exceptionally in the 2020–2021 season; the average positivity rate in week 52–3 was the average of five weeks (52, 53, 1, 2, and 3). *: \( p < 0.05 \), comparison between averages for three previous seasons, 2016–2017 through 2018–2019 and the COVID-19 pandemic (2019–2020); *: \( p < 0.05 \); comparison between averages for three previous seasons, 2016–2017 through 2018–2019 and the COVID-19 pandemic (2020–2021).
4. Discussion

The emergence of the COVID-19 pandemic triggered a lot of interest from scientists on understanding the relationships between SARS-CoV-2 infection and infections with other respiratory viruses and on predicting what influenza viruses would emerge following the COVID-19 pandemic [16,17]. In the present study, we report the impact of the COVID-19 pandemic and its associated NPIs on laboratory-confirmed detections of influenza and other seasonal respiratory viruses among the Department of Defense personnel in the United States. It is evident from the analysis that the patterns of seasonal respiratory viruses have substantially changed during the COVID-19 pandemic.

The seasonal cycle of respiratory viral infections has been widely recognized [18]. Nevertheless, after implementing NPIs in response to the first wave of the COVID-19 pandemic in the United States, the 2019–2020 influenza season terminated earlier, and most of the seasonal respiratory viruses were suppressed in the early phase of the pandemic in 2020. Consistently, previous studies [19,20] observed a dramatic decrease in seasonal respiratory viruses in the similar period of time. Moreover, it was reported that following the end of the 2019–2020 season, the circulation of influenza and most of the other seasonal respiratory viruses continued to be very low through early 2021 [4,21,22]. In contrast, rhinovirus/enterovirus behaved differently. Studies in other countries [9,19,23] have similar observations showing a rhinovirus resurgence once preventive measures were being loosened during the pandemic in 2020. In addition, Groves et al. [21] observed the continued detection of rhinovirus/enterovirus in Canada through early 2021. The reason causing the difference in rhinovirus circulation in comparison with other seasonal respiratory viruses during the COVID-19 pandemic is unclear. Rhinovirus is a structurally non-enveloped virus, circulating year-round throughout the world [24]. A possible explanation for this phenomenon is non-enveloped rhinovirus may be less susceptible to preventive measures such as hand washing and surface cleaning [25]. In addition, the transmission of rhinovirus occurs by droplets or aerosols, or through direct contact or a fomite [24,26]. Rhinovirus may have more preferable transmission routes; thus, more stringent NPIs are likely required to prevent it from spreading, compared to other seasonal respiratory viruses.

What is notable in the present study is typical winter viruses, such as seasonal coronavirus and RSV [18], returned out of season in 2021 (Figure 1E,H and Figure 3B,E). Moreover, infections with parainfluenza viruses, which were at very low levels for around 12 months since the start of the COVID-19 pandemic, have started to surge in the spring of 2021 in the settings of relaxed NPIs (Figures 1G and 3D). Off-season increased RSV activity has been observed in Australia [27,28] in 2020. In addition, RSV activity has increased in many parts of the United States in the spring of 2021 [4,12,29]. It is unknown for certain what caused the respiratory viruses like RSV to surge out of season. It is possible that RSVs have almost completely disappeared for a year since NPIs were put in place during the pandemic resulting in waning immunity. Then, the reduced immunity led to a potentially large part of the population being more susceptible to RSV infection. Further, the relaxation of NPIs in the United States in the spring of 2021 gave the virus an opportunity to spike. The finding that the easing of NPIs has led to the reemergence of seasonal respiratory viruses highlights the effectiveness of NPIs in preventing the spread of respiratory viruses [29]. Interestingly, we observed a sudden increased activity of influenza A(H3N2) during the last three weeks of the 2020–2021 season (Figure 1B). All of the influenza A(H3N2) infections occurred in the same location in the eastern US. It is unclear whether the influenza A(H3N2) infections indicate that the spreading of influenza is under way. However, it was warned that influenza in the winter 2021/2022 could be around twice the magnitude of a ‘normal’ year [30].

The present study is subject to several limitations. First, it relies on the DoDGRS program for data acquisition. The specimens were collected through routine outpatient clinical care from the sentinel and participating sites in the DoDGRS program. The possibility of potential case selection bias could not be ruled out in the pre-pandemic period or during the COVID-19 pandemic. Second, potential changes in specimen sampling eligibility
driven by the COVID-19 pandemic might occur, which could result in a difference in the
detection of influenza and other seasonal respiratory viruses compared to those in the
pre-pandemic. Third, the healthcare-seeking behavior might have been changed related to
SARS-CoV-2 concerns. Patients with respiratory viral infections appeared more likely to
take SARS-CoV-2 testing rather than testing for influenza and other seasonal respiratory
viruses as before. This might partially explain the lower number of influenza and other
seasonal respiratory viruses’ testing during the 2020–2021 respiratory season (Table 2).
Another contributing factor could be that the laboratories in sentinel or participating sites
might have been overburdened by the large scale of testing for SARS-CoV-2, consequently
leading to reduced testing for seasonal respiratory viruses [21].

5. Conclusions

In conclusion, the present study demonstrates that the COVID-19 pandemic and its
associated NPIs have exerted tremendous impacts on the circulations of influenza and other
seasonal respiratory viruses. The findings, based on the analysis of a database from the
DoDGRS program, make significant additions to the growing evidence that NPIs may be an
effective public health tool in reducing the spreading of seasonal respiratory viruses. The
reason for the dramatic decrease in transmissions of influenza and other seasonal respiratory
viruses during the COVID-19 pandemic remains unclear. In addition, little is known as to why
some respiratory viruses (seasonal coronavirus, RSV) rebounded out of season following the
easing of NPIs. Further study is needed to explore and thus have a better understanding of the
underlying mechanisms for altering circulation patterns of seasonal respiratory viruses. With
the ongoing COVID-19 pandemic, it is important to evaluate transmission dynamics and risks
of influenza and other seasonal respiratory viruses in subsequent respiratory seasons. Indeed,
assessing the exact prevalence of respiratory viruses in the real world would undoubtedly
provide valuable information, and help guide the design of preventive measures in mitigating
seasonal respiratory virus epidemics.

Author Contributions: Conceptualization, W.H., A.C.F., L.S.D., P.A.S. and A.S.R.; Data curation,
W.H., L.S.D., J.W.T., B.K. and K.N.B.; Formal analysis, W.H.; Investigation, W.H., A.C.F., L.S.D., P.A.S.
and A.S.R.; Methodology, W.H., A.C.F., P.A.S. and A.S.R.; Validation, W.H., A.C.F., L.S.D., J.W.T.,
B.K., K.N.B., P.A.S. and A.S.R.; Writing—original draft, W.H.; Writing—review and editing, W.H.,
A.C.F., L.S.D., J.W.T., B.K., K.N.B., P.A.S. and A.S.R. All authors have read and agreed to the published
version of the manuscript.

Funding: The US Department of Defense Global Emerging Infections Surveillance Branch (DoDGEIS),
Armed Forces Health Surveillance Division (AFHSD) funds the Department of Defense Global
Respiratory Pathogen Surveillance (DoDGRS) Program at the US Air Force School of Aerospace
Medicine at Wright-Patterson Air Force Base in Dayton, OH. JYG Innovations, LLC provided support
in the form of salary for authors (W.H., L.S.D., J.W.T., B.K., K.N.B., and P.A.S.).

Institutional Review Board Statement: The present study was determined to be “Public Health
Practice” and “Not Human Use Research”, and was exempted from review by the Department of
Defense Air Force Research Laboratory’s Institutional Review Board. Regulations or rules were
followed to protect each patient’s identity and health information.

Informed Consent Statement: Not applicable.

Data Availability Statement: All data are presented in this article. For further information, contact
the corresponding author.

Acknowledgments: The authors would like to thank the Department of Defense Global Respiratory
Pathogen Surveillance Program and its sentinel and participating site partners, and the US Air Force
School of Aerospace Medicine Epidemiology Laboratory for their contribution and support in the
collection, collation, and reporting of surveillance data.

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design
of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or
in the decision to publish the results.
Disclaimer: The views expressed are those of the authors and do not reflect the official guidance or position of the United States Government, the Department of Defense, or of the United States Air Force.

References

1. Avadhanula, V.; Piedra, P.A. The prevention of common respiratory virus epidemics in 2020–21 during the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic: An unexpected benefit of the implementation of public health measures. Lancet Reg. Health-Am. 2021, 2, 100043. [CrossRef] [PubMed]

2. Lai, S.; Ruktanonchai, N.W.; Zhou, L.; Prosper, O.; Luo, W.; Floyd, J.R.; Wesolowski, A.; Santillana, M.; Zhang, C.; Du, X.; et al. Effect of non-pharmaceutical interventions to contain COVID-19 in China. Nature 2020, 585, 410–413. [CrossRef] [PubMed]

3. Flaxman, S.; Mishra, S.; Gandy, A.; Unwin, H.J.T.; Mellan, T.A.; Coupland, H.; Whittaker, C.; Zhu, H.; Berah, T.; Eaton, J.W.; et al. Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe. Nature 2020, 584, 257–261. [CrossRef] [PubMed]

4. Olsen, S.J.; Winn, A.K.; Budd, A.P.; Prill, M.M.; Steel, J.; Midgley, C.M.; Kniss, K.; Burns, E.; Rowe, T.; Foust, A.; et al. Changes in influenza and other respiratory virus activity during the COVID-19 pandemic-United States, 2020–2021. MMWR 2021, 70, 1013–1019. [PubMed]

5. Arellanos-Soto, D.; Padilla-Rivas, G.; Ramos-Jimenez, J.; Galan-Huerta, K.; Lozano-Sepulveda, S.; Martinez-Acuña, N.; Treviño-Garza, C.; Montes-de-Oca-Luna, R.; de-la-O-Cavazos, M.; Rivas-Estilla, A.M. Decline in influenza cases in Mexico after the implementation of public health measures for COVID-19. Sci. Rep. 2021, 11, 10730. [CrossRef]

6. Lee, H.; Lee, H.; Song, K.-H.; Kim, E.S.; Park, J.S.; Jung, J.; Ahn, S.; Jeong, E.K.; Park, H.; Kim, H.B. Impact of public health interventions on seasonal influenza activity during the COVID-19 outbreak in Korea. Clin. Infect. Dis. 2021, 73, e132–e140. [CrossRef]

7. Emborg, H.-D.; Carnahan, A.; Bragstad, K.; Trebbien, R.; Brytting, M.; Hungnes, O.; Byström, E.; Vestergaard, L.S. Abrupt termination of the 2019/20 influenza season following preventive measures against COVID-19 in Denmark, Norway and Sweden. Eurosurveillance 2021, 26, 2001160. [CrossRef]

8. Olsen, S.J.; Azziz-Baumgartner, E.; Budd, A.P.; Brammer, L.; Sullivan, S.; Pineda, R.F.; Cohen, C.; Fry, A.M. Decreased influenza activity during the COVID-19 pandemic-United States, Australia, Chile, and South Africa, 2020. MMWR 2020, 69, 1305–1309.

9. Huang, Q.S.; Wood, T.; Jelley, L.; Jennings, T.; Jefferies, S.; Daniells, K.; Neadle, A.; Dowell, T.; Turner, N.; Campbell-Stokes, P.; et al. Impact of the COVID-19 nonpharmaceutical interventions on influenza and other respiratory viral infections in New Zealand. Nat. Commun. 2021, 12, 1001. [CrossRef]

10. Sullivan, S.G.; Carlson, S.; Cheng, A.C.; Chilver, M.B.N.; Dwyer, D.E.; Irwin, M.; Kok, J.; Macartney, K.; MacLachlan, J.; Minney-Smith, C.; et al. Where has all the influenza gone? The impact of COVID-19 on the circulation of influenza and other respiratory viruses, Australia, March to September 2020. Eurosurveillance 2020, 25, 2001847. [CrossRef]

11. Tempia, S.; Walaza, S.; Bhiman, J.N.; McMorrow, M.L.; Moyes, J.; Mkhencele, T.; Meiring, S.; Quan, V.; Bishop, K.; McAnerny, J.M.; et al. Decline of influenza and respiratory syncytial virus detection in facility-based surveillance during the COVID-19 pandemic, South Africa, January to October 2020. Eurosurveillance 2021, 26, 2001600. [CrossRef] [PubMed]

12. Agha, R.; Avner, I.R. Delayed seasonal RSV surge observed during the COVID-19 pandemic. Pediatrics 2021, 148, e2021052089. [CrossRef] [PubMed]

13. Casalegno, J.-S.; Ploin, D.; Cantais, A.; Masson, E.; Bard, E.; Valette, M.; Fanget, R.; Targe, S.C.; Myar-Dury, A.-F.; Doret-Dion, M.; et al. Characteristics of the delayed respiratory syncytial virus epidemic, 2020/2021, Rhône Loire, France. Eurosurveillance 2021, 26, 2100630. [CrossRef] [PubMed]

14. Van Summeren, J.; Meijer, A.; Aspelund, G.; Casalegno, J.S.; Erna, G.; Hoang, U.; Lina, B.; VRS study group in Lyon; de Lusignan, S.; Teirlinck, A.C.; et al. Low levels of respiratory syncytial virus activity in Europe during the 2020/21 season: What can we expect in the coming summer and autumn/winter? Eurosurveillance 2021, 26, 2100639. [CrossRef]

15. Feng, L.; Zhang, T.; Wang, Q.; Xie, Y.; Peng, Z.; Zheng, J.; Qin, Y.; Zhang, M.; Lai, S.; Wang, D.; et al. Impact of COVID-19 outbreaks and interventions on influenza in China and the United States. Nat. Commun. 2021, 12, 3249. [CrossRef]

16. Laurie, K.L.; Rockman, S. Which influenza viruses will emerge following the SARS-CoV-2 pandemic? Influenza Other Respir. Viruses 2021, 15, 573–576. [CrossRef]

17. Gomez, G.B.; Mahé, C.; Chaves, S.S. Uncertain effects of the pandemic on respiratory viruses. Science 2021, 372, 1043–1044. [CrossRef]

18. Moriyma, M.; Hugentobler, W.J.; Iwasaki, A. Seasonality of Respiratory Viral Infections. Annu. Rev. Virol. 2020, 7, 83–101. [CrossRef]

19. Oh, D.-Y.; Buda, S.; Biere, B.; Reiche, J.; Schlosser, F.; Duve, S.; Wedde, M.; von Kleist, M.; Mielke, M.; Wolff, T.; et al. Trends in respiratory virus circulation following COVID-19-targeted nonpharmaceutical interventions in Germany, January-September 2020: Analysis of national surveillance data. Lancet Reg. Health-Eur. 2021, 6, 100112. [CrossRef]

20. Doroshenko, A.; Lee, N.; MacDonald, C.; Zelyas, N.; Asadi, L.; Kanji, J.N. Decline of influenza and respiratory viruses with COVID-19 public health measures: Alberta, Canada. Mayo Clin. Proc. 2021, 96, 3042–3052. [CrossRef]

21. Groves, H.E.; Piché-Renaud, P.-P.; Peci, A.; Farrar, D.S.; Buckrell, S.; Bancej, C.; Sevenhuyzen, C.; Campigotto, A.; Gubbay, J.B.; Morris, S.K. The impact of the COVID-19 pandemic on influenza, respiratory syncytial virus and other seasonal respiratory virus circulation in Canada: A population-based study. Lancet Reg. Health-Am. 2021, 1, 100015. [PubMed]
22. Park, K.Y.; Seo, S.; Han, J.; Park, J.Y. Respiratory virus surveillance in Canada during the COVID-19 pandemic: An epidemiological analysis of the effectiveness of pandemic-related public health measures in reducing seasonal respiratory viruses test positivity. *PLoS ONE* 2021, 16, e0253451. [CrossRef] [PubMed]

23. Poole, S.; Brendish, N.J.; Tanner, A.R.; Clark, T.W. Physical distancing in schools for SARS-CoV-2 and the resurgence of rhinovirus. *Lancet Respir. Med.* 2020, 8, e92–e93. [CrossRef]

24. Kiseleva, I.; Ksenafontov, A. COVID-19 shuts doors to flu but keeps them open to rhinoviruses. *Biology* 2021, 10, 733. [CrossRef]

25. Britton, P.N.; Hu, N.; Saravanan, G.; Shrapnel, J.; Davis, J.; Snelling, T.; Dalby-Payne, J.; Kesson, A.M.; Wood, N.; Macartney, K.; et al. COVID-19 public health measures and respiratory syncytial virus. *Lancet Child Adolesc. Health* 2020, 4, e42–e43. [CrossRef]

26. Jacobs, S.E.; Lamson, D.M.; St. George, K.; Walsh, T.J. Human rhinoviruses. *Clin. Microbiol. Rev.* 2013, 26, 135–162. [CrossRef]

27. McNab, S.; Do, L.A.H.; Clifford, V.; Crawford, N.W.; Daley, A.; Mulholland, K.; Cheng, D.; South, M.; Waller, G.; Barr, I.; et al. Changing epidemiology of respiratory syncytial virus in Australia-delayed re-emergence in Victoria compared to Western Australia/New South Wales (WA/NSW) after prolonged lock-down for coronavirus disease 2019 (COVID-19). *Clin. Infect. Dis.* 2021, 73, 2365–2366. [CrossRef]

28. Foley, D.A.; Yeoh, D.K.; Minney-Smith, C.A.; Martin, A.C.; Mace, A.O.; Sikazwe, C.T.; Le, H.; Levy, A.; Moore, H.C.; Blyth, C.C. The interseasonal resurgence of respiratory syncytial virus in Australian children following the reduction of coronavirus disease 2019-related public health measures. *Clin. Infect. Dis.* 2021, 73, e2829–e2830. [CrossRef]

29. Hodjat, P.; Christensen, P.A.; Subedi, S.; Bernard, D.W.; Olsen, R.J.; Long, S.W. The re-emergence of seasonal respiratory viruses in Houston, Texas, after relaxing COVID-19 restrictions. *Microbiol. Spectr.* 2021, 9, e00430-21. [CrossRef]

30. The Academy of Medical Sciences. COVID-19: Preparing for the Future. Looking Ahead to Winter 2021/22 and Beyond; The Academy of Medical Sciences: London, UK, 2021; pp. 4–9.